ପ୍ରୋଟନ୍-ପମ୍ପ ଇନହିବିଟର

ପ୍ରୋଟନ୍-ପମ୍ପ ଇନହିବିଟର
ପ୍ରୋଟନ୍-ପମ୍ପ ଇନହିବିଟର
Drug class
	General structure of a proton-pump inhibitor
Class identifiers
Use	Peptic ulcers, gastroesophageal reflux disease (GERD), H. pylori infection
Mechanism of action	Enzyme inhibitor
Biological target	H+/K+ ATPase
Clinical data
Drugs.com	Drug Classes
WebMD	MedicineNet
	In Wikidata

ପ୍ରୋଟନ୍-ପମ୍ପ ଇନହିବିଟର ( PPIs ) ହେଉଛି ଏକ ଔଷଧ ଶ୍ରେଣୀ ଯାହା ଅମ୍ଳରୋଗ, ଗ୍ୟାଷ୍ଟ୍ରୋଏସୋଫେଜିଅଲ ରିଫ୍ଲକ୍ସ ରୋଗ (GERD) ଏବଂ ଏଚ୍ ପାଇଲୋରି ସଂକ୍ରମଣ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହି ଔଷଧ ଶ୍ରେଣୀରେ ଓମେପ୍ରାଜୋଲ, ପାଣ୍ଟୋପ୍ରାଜୋଲ, ରାବେପ୍ରାଜୋଲ, ଲାନ୍ସୋପ୍ରାଜୋଲ, ଏସୋମେପ୍ରାଜୋଲ ଏବଂ ଡେକ୍ସଲାନ୍ସୋପ୍ରାଜୋଲ ଅନ୍ତର୍ଭୁକ୍ତ ଅଛନ୍ତି ।^[୨] କୌଣସି ଗୋଟିଏ ଔଷଧ ଅନ୍ୟଟି ଅପେକ୍ଷା ଭଲ ଥିବାର କୌଣସି ସ୍ପଷ୍ଟ ପ୍ରମାଣ ନାହିଁ ।^[୩] ^[୪] ସେଗୁଡିକ ପାଟିରେ ଦିଆଯାଇପାରେ କିମ୍ବା ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଇପାରେ ।^[୧]

ଏହି ଔଷଧ ଶ୍ରେଣୀଗୁଡ଼ିକ ସାଧାରଣତଃ ବିପଦମୁକ୍ତ ଅଟନ୍ତି ।^[୨] ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ପେଟ ଗୋଳମାଳ ଏବଂ ସ୍ୱାଦର ପରିବର୍ତ୍ତନ ହୋଇପାରେ ।^[୧] ^[୨] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବୃକ୍‌କ ବିଫଳତା, ଅଷ୍ଟିଓପୋରୋସିସ୍, କମ୍ ମ୍ୟାଗ୍ନେସିୟମ୍ ସ୍ତର ଏବଂ କ୍ଲୋଷ୍ଟ୍ରିଡିଅମ ଡିଫିସିଲ ଅନ୍ତର୍ଗତ ତରଳ ଝାଡ଼ା ହୋଇପାରେ । ^[୧] ^[୨] କ୍ଲୋପିଡୋଗ୍ରେଲ ସହିତ ପାରସ୍ପରିକ କ୍ରିୟା ବିଷୟରେ ଚିନ୍ତା ଉଠିଥିବାବେଳେ ଏହାର ଭିତ୍ତି ଅସ୍ପଷ୍ଟ ଅଛି ।^[୫]

ପାକସ୍ଥଳୀରେ ଉତ୍ପାଦନ ହେଉଥିବା ଅମ୍ଳ ପରିମାଣ ହ୍ରାସ କରି ସେମାନେ କାର୍ଯ୍ୟକ୍ଷମ ହୁଅନ୍ତି ।^[୧] ସେମାନେ ଏଚ+/ କେ+ ଏଟିପେଜକୁ ( H + / K + ATPaseକୁ) ଅବରୋଧ କରି ଏହି କାର୍ଯ୍ୟ ସମ୍ପନ୍ନ କରନ୍ତି ।^[୧] ସେମାନେ ଉପଲବ୍ଧ ଅମ୍ଳ ସ୍ରାବର ଶକ୍ତିଶାଳୀ ପ୍ରତିବନ୍ଧକ ।^[୬] ଏଚ2 -ରିସେପ୍ଟର ଆଣ୍ଟାଗୋନିଷ୍ଟ ଅପେକ୍ଷା ଏହି ଗୋଷ୍ଠୀ ପାକସ୍ଥଳୀ ଅମ୍ଲ ଅଧିକ ହ୍ରାସ କରେ ।^[୭]

ଏହି ଗୋଷ୍ଠୀର ପ୍ରଥମ ଉପଯୋଗୀ ଔଷଧ ଓମେପ୍ରାଜୋଲ ୧୯୭୯ ମସିହାରେ ତିଆରି କରାଯାଇଥିଲା ।^[୮] ତାହାର ନାମ ବହୁଳ ବ୍ୟବ‌ହୃତ ଔଷଧ ମଧ୍ୟରେ ଅଛି ।^[୧] ଏହି ଶ୍ରେଣୀର ଓମେପ୍ରାଜୋଲ ନାମକ ଏକ ଔଷଧ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଅଛି ।^[୯] କେତେକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ଏବଂ ଅପେକ୍ଷାକୃତ ଶସ୍ତା | ^[୧]

ଆଧାର

↑ ^୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (in ଇଂରାଜୀ) (2nd ed.). Elsevier. p. 194. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "List of Proton Pump Inhibitors + Uses, Side Effects". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 August 2021. Retrieved 12 March 2021.
↑ "[99] Comparative effectiveness of proton pump inhibitors". Therapeutics Letter. 28 June 2016. ISSN 2369-8691. Archived from the original on 9 July 2016. Retrieved 14 July 2016.
↑ Dean, Laura (1 October 2010). Comparing Proton Pump Inhibitors. National Center for Biotechnology Information (US). Archived from the original on 8 March 2018. Retrieved 16 July 2016. {{cite book}}: |work= ignored (help)
↑ "What is the clinical relevance of the clopidogrel/proton pump inhibitor (PPI) interaction?". 2019. Archived from the original on 27 September 2020. Retrieved 13 March 2021.
↑ Sachs, G.; Shin, J. M.; Howden, C. W. (2006). "Review article: The clinical pharmacology of proton pump inhibitors". Alimentary Pharmacology and Therapeutics. 23: 2–8. doi:10.1111/j.1365-2036.2006.02943.x. PMID 16700898.
↑ Hauser, Stephen C.; Pardi, Darrell S.; Poterucha, John J. (2005). Mayo Clinic Gastroenterology and Hepatology Board Review (in ଇଂରାଜୀ). CRC Press. p. 18. ISBN 978-0-203-50274-7. Archived from the original on 2021-08-29. Retrieved 2021-03-13.
↑ Olbe, Lars (1999). Proton Pump Inhibitors (in ଇଂରାଜୀ). Springer Science & Business Media. p. 17. ISBN 978-3-7643-5897-6. Archived from the original on 2021-08-29. Retrieved 2021-03-13.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Hitch2019-1] ୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (in ଇଂରାଜୀ) (2nd ed.). Elsevier. p. 194. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.

[Drugs2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "List of Proton Pump Inhibitors + Uses, Side Effects". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 August 2021. Retrieved 12 March 2021.

[TI(99)2016-3] "[99] Comparative effectiveness of proton pump inhibitors". Therapeutics Letter. 28 June 2016. ISSN 2369-8691. Archived from the original on 9 July 2016. Retrieved 14 July 2016.

[De2010-4] Dean, Laura (1 October 2010). Comparing Proton Pump Inhibitors. National Center for Biotechnology Information (US). Archived from the original on 8 March 2018. Retrieved 16 July 2016. {{cite book}}: |work= ignored (help)

[5] "What is the clinical relevance of the clopidogrel/proton pump inhibitor (PPI) interaction?". 2019. Archived from the original on 27 September 2020. Retrieved 13 March 2021.

[pmid16700898-6] Sachs, G.; Shin, J. M.; Howden, C. W. (2006). "Review article: The clinical pharmacology of proton pump inhibitors". Alimentary Pharmacology and Therapeutics. 23: 2–8. doi:10.1111/j.1365-2036.2006.02943.x. PMID 16700898.

[7] Hauser, Stephen C.; Pardi, Darrell S.; Poterucha, John J. (2005). Mayo Clinic Gastroenterology and Hepatology Board Review (in ଇଂରାଜୀ). CRC Press. p. 18. ISBN 978-0-203-50274-7. Archived from the original on 2021-08-29. Retrieved 2021-03-13.

[8] Olbe, Lars (1999). Proton Pump Inhibitors (in ଇଂରାଜୀ). Springer Science & Business Media. p. 17. ISBN 978-3-7643-5897-6. Archived from the original on 2021-08-29. Retrieved 2021-03-13.

[WHO21st-9] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]